Patrick S Parfrey1, Tilman B Drüeke2, Geoffrey A Block3, Ricardo Correa-Rotter4, Jürgen Floege5, Charles A Herzog6, Gerard M London7, Kenneth W Mahaffey8, Sharon M Moe9, David C Wheeler10, Yumi Kubo11, Bastian Dehmel11, William G Goodman11, Glenn M Chertow8. 1. Department of Medicine, Health Sciences Center, St. John's, Newfoundland, Canada; pparfrey@mun.ca. 2. French Institute of Health and Medical Research Unit 1088, Faculty of Medicine and Pharmacy, University of Picardie, Amiens, France; 3. Denver Nephrology, Denver, Colorado; 4. Department of Nephrology and Mineral Metabolism, Salvador Zubirán National Institute of Health Sciences and Nutrition, Mexico City, Mexico; 5. Department of Nephrology, RWTH Aachen University Hospital, Aachen, Germany; 6. Department of Internal Medicine, University of Minnesota, Minneapolis, Minnesota; 7. Service of Nephrology, Manhès Hospital, Paris, France; 8. Department of Medicine, Stanford University School of Medicine, Palo Alto, California; 9. Department of Medicine, Indiana University School of Medicine and Roudebush Veterans Administration Medical Center, Indianapolis, Indiana; 10. Centre for Nephrology, University College London, United Kingdom; and. 11. Amgen Inc, Thousand Oaks, California.
Abstract
BACKGROUND AND OBJECTIVES: The calcimimetic cinacalcet reduced the risk of death or cardiovascular (CV) events in older, but not younger, patients with moderate to severe secondary hyperparathyroidism (HPT) who were receiving hemodialysis. To determine whether the lower risk in younger patients might be due to lower baseline CV risk and more frequent use of cointerventions that reduce parathyroid hormone (kidney transplantation, parathyroidectomy, and commercial cinacalcet use), this study examined the effects of cinacalcet in older (≥65 years, n=1005) and younger (<65 years, n=2878) patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) was a global, multicenter, randomized placebo-controlled trial in 3883 prevalent patients on hemodialysis, whose outcomes included death, major CV events, and development of severe unremitting HPT. The age subgroup analysis was prespecified. RESULTS:Older patients had higher baseline prevalence of diabetes mellitus and CV comorbidity. Annualized rates of kidney transplantation and parathyroidectomy were >3-fold higher in younger relative to older patients and were more frequent in patients randomized to placebo. In older patients, the adjusted relative hazard (95% confidence interval) for the primary composite (CV) end point (cinacalcet versus placebo) was 0.70 (0.60 to 0.81); in younger patients, the relative hazard was 0.97 (0.86 to 1.09). Corresponding adjusted relative hazards for mortality were 0.68 (0.51 to 0.81) and 0.99 (0.86 to 1.13). Reduction in the risk of severe unremitting HPT was similar in both groups. CONCLUSIONS: In the EVOLVE trial, cinacalcet decreased the risk of death and of major CV events in older, but not younger, patients with moderate to severe HPT who were receiving hemodialysis. Effect modification by age may be partly explained by differences in underlying CV risk and differential application of cointerventions that reduce parathyroid hormone.
RCT Entities:
BACKGROUND AND OBJECTIVES: The calcimimetic cinacalcet reduced the risk of death or cardiovascular (CV) events in older, but not younger, patients with moderate to severe secondary hyperparathyroidism (HPT) who were receiving hemodialysis. To determine whether the lower risk in younger patients might be due to lower baseline CV risk and more frequent use of cointerventions that reduce parathyroid hormone (kidney transplantation, parathyroidectomy, and commercial cinacalcet use), this study examined the effects of cinacalcet in older (≥65 years, n=1005) and younger (<65 years, n=2878) patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) was a global, multicenter, randomized placebo-controlled trial in 3883 prevalent patients on hemodialysis, whose outcomes included death, major CV events, and development of severe unremitting HPT. The age subgroup analysis was prespecified. RESULTS: Older patients had higher baseline prevalence of diabetes mellitus and CV comorbidity. Annualized rates of kidney transplantation and parathyroidectomy were >3-fold higher in younger relative to older patients and were more frequent in patients randomized to placebo. In older patients, the adjusted relative hazard (95% confidence interval) for the primary composite (CV) end point (cinacalcet versus placebo) was 0.70 (0.60 to 0.81); in younger patients, the relative hazard was 0.97 (0.86 to 1.09). Corresponding adjusted relative hazards for mortality were 0.68 (0.51 to 0.81) and 0.99 (0.86 to 1.13). Reduction in the risk of severe unremitting HPT was similar in both groups. CONCLUSIONS: In the EVOLVE trial, cinacalcet decreased the risk of death and of major CV events in older, but not younger, patients with moderate to severe HPT who were receiving hemodialysis. Effect modification by age may be partly explained by differences in underlying CV risk and differential application of cointerventions that reduce parathyroid hormone.
Authors: Xin Sun; Matthias Briel; Jason W Busse; John J You; Elie A Akl; Filip Mejza; Malgorzata M Bala; Dirk Bassler; Dominik Mertz; Natalia Diaz-Granados; Per Olav Vandvik; German Malaga; Sadeesh K Srinathan; Philipp Dahm; Bradley C Johnston; Pablo Alonso-Coello; Basil Hassouneh; Stephen D Walter; Diane Heels-Ansdell; Neera Bhatnagar; Douglas G Altman; Gordon H Guyatt Journal: BMJ Date: 2012-03-15
Authors: W N Suki; R Zabaneh; J L Cangiano; J Reed; D Fischer; L Garrett; B N Ling; S Chasan-Taber; M A Dillon; A T Blair; S K Burke Journal: Kidney Int Date: 2007-08-29 Impact factor: 10.612
Authors: Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; William G Goodman; Charles A Herzog; Yumi Kubo; Gerard M London; Kenneth W Mahaffey; T Christian H Mix; Sharon M Moe; Marie-Louise Trotman; David C Wheeler; Patrick S Parfrey Journal: N Engl J Med Date: 2012-11-03 Impact factor: 91.245
Authors: Geoffrey A Block; Kevin J Martin; Angel L M de Francisco; Stewart A Turner; Morrell M Avram; Michael G Suranyi; Gavril Hercz; John Cunningham; Ali K Abu-Alfa; Piergiorgio Messa; Daniel W Coyne; Francesco Locatelli; Raphael M Cohen; Pieter Evenepoel; Sharon M Moe; Albert Fournier; Johann Braun; Laura C McCary; Valter J Zani; Kurt A Olson; Tilman B Drüeke; William G Goodman Journal: N Engl J Med Date: 2004-04-08 Impact factor: 91.245
Authors: Patrick S Parfrey; Glenn M Chertow; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; Charles A Herzog; Gerard M London; Kenneth W Mahaffey; Sharon M Moe; David C Wheeler; Bastian Dehmel; Marie-Louise Trotman; Dennis M Modafferi; William G Goodman Journal: J Clin Endocrinol Metab Date: 2013-10-09 Impact factor: 5.958
Authors: Martin Schepelmann; Marianna Ranieri; Irene Lopez-Fernandez; Thomas S Webberley; Sarah C Brennan; Polina L Yarova; Joao Graca; Umar-Khetaab Hanif; Christian Müller; Teresa Manhardt; Martina Salzmann; Helen Quasnichka; Sally A Price; Donald T Ward; Thierry Gilbert; Vladimir V Matchkov; Robert A Fenton; Amanda Herberger; Jenna Hwong; Christian Santa Maria; Chia-Ling Tu; Enikö Kallay; Giovanna Valenti; Wenhan Chang; Daniela Riccardi Journal: J Am Soc Nephrol Date: 2022-05-17 Impact factor: 14.978
Authors: Patrick S Parfrey; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; Charles A Herzog; Gerard M London; Kenneth W Mahaffey; Sharon M Moe; David C Wheeler; Glenn M Chertow Journal: Clin J Am Soc Nephrol Date: 2015-11-27 Impact factor: 8.237
Authors: Jordi Bover; Pablo Ureña; César Ruiz-García; Iara daSilva; Patricia Lescano; Jacqueline del Carpio; José Ballarín; Mario Cozzolino Journal: Clin J Am Soc Nephrol Date: 2015-07-29 Impact factor: 8.237